Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-04
2006-04-04
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S199000, C546S256000, C514S338000, C548S304700, C548S306100
Reexamination Certificate
active
07022714
ABSTRACT:
This invention relates aryl substituted benzimidazoles of Formula I:or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1, R2, R10and n are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
REFERENCES:
patent: 4297365 (1981-10-01), Rajappa et al.
patent: 6211177 (2001-04-01), Sperl et al.
patent: 6335354 (2002-01-01), Hogenkamp
patent: 6414011 (2002-07-01), Hogenkamp et al.
patent: 2002/0006947 (2002-01-01), Hogenkamp et al.
patent: 2002/0022624 (2002-02-01), Dinnell et al.
patent: 2002/0040025 (2002-04-01), Hogenkamp et al.
patent: 2003/0055088 (2003-03-01), Shao et al.
patent: 2003/0069292 (2003-04-01), Hogenkamp et al.
patent: 2003/0073724 (2003-04-01), Shao et al.
patent: 2003/0109521 (2003-06-01), Sun et al.
patent: 2003/0236273 (2003-12-01), Goehring et al.
patent: 2004/0002523 (2004-01-01), Hogenkamp et al.
patent: 2000-323278 (2000-11-01), None
patent: WO 98/08818 (1999-02-01), None
patent: WO 99/43672 (1999-02-01), None
patent: WO 01/21634 (2001-03-01), None
patent: WO 01/83472 (2001-11-01), None
Laird, et al., “Analgesic Activity of a Novel Use-Dependent Sodium Channel Blocker, Crobenetine, in Mono-arthritic Rats,” Br. J. Pharmacol. (2001) 134, 1742-1748.
Bensimon, G., et al., “A Controlled Trail of Riluzole in Amyotrophic Lateral Sclerosis,”New Engl. J. Med.330:585-591, Massachusetts Medical Society (1994).
Brown, C.M., et al., “Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia,”British J. Pharmacol.115:1425-1432, Stockton Press (1995).
Catterall, W.A., “Neurotoxins that Act on Voltage-Sensitive Channels in Excitable Membranes,”Ann. Rev. Pharmacol. Toxicol.20:15-43, Annual Reviews, Inc. (1980).
Catterall, W.A., “Structure and Function of Voltage-Sensitive Ion Channels,”Science242:50-61, American Association for the Advancement of Science (1988).
Catterall, W.A., “Common modes of drug action on NA+channels: local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci.8:57-65, Elsevier Science Publishers (1987).
Denicoff, K.D., et al., “Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey,”J. Clin. Psychiatry55:70-76, Physicians Postgraduate Press (1994).
Donaldson, I., “Tegretol: A double blind trial in tinnitus,”J. Laryngol. Otol.95:947-951, Journal of Laryngology and Otology Ltd. (1981).
Graham, S.H., et al., “Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion,”J. Pharmacol. Exp. Ther.269:854-859, The American Society of Pharmacology and Experimental Therapeutics (1994).
Majumdar, B., et al., “An electrocochleographic study of the effects of lignocaine on patients with tinnitus,”Clin. Otolaryngol.8:175-180, Blackwell Scientific Publications (1983).
Mane, D.V., et al., “Synthesis and biological activity of some new 2-alkyl-1-(1′-dihydropyridylmethyl)benzimidazoles,”Indian J. Chem.34B:917-919, The Council of Scientific & Industrial Research (1995).
Moller, A.R., “Similarities Between Chronic Pain and Tinnitus,”Am. J. Otol.18:577-585, American Journal of Otology, Inc. (1997).
Simpson, J.J., and Davies, W.E., “Recent advances in the pharmacological treatment of tinnitus,”TIPS20:12-18, Elsevier Science (1999).
Srivastava, A.J., et al., “Synthesis and Antiviral Activity of Mannich Bases of 2-[(2-Oxo-4-Methyl-7-HydroxyQuinolinyl)-1-(4′-aryl)] Benzimidazole,”Indian Drugs28:75-77, Indian Drug Manufacturers' Association (1990).
Stys, P.K., et al., “Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na+Channels and Na+-Ca2+Exchanger,”J. Neurosci.12:430-439, Society for Neuroscience (1992).
Taylor, C.P., and Meldrum, B.S., “Na+channels as targets for neuroprotective drugs,”Trends Pharmacol. Sci.16:309-316, Elsevier Science Ltd. (1995).
Tonndorf, J., “The analogy between tinnitus and pain: A suggestion for a physiological basis of chronic tinnitus,”Hear. Res.28:271-275, Elsevier Science Publishers (1987).
English language abstract of EP 0 639 573 A1, Derwent World Patents Index (Dialog File 351), WPI Accession No. 10182147 , (2003).
English language abstract of JP 2000323278, Derwent World Patents Index (Dialog File 351), WPI Accession No. 13736273, (2003).
International Search Report for PCT Application No. PCT/US 03/23828, mailed on January 20, 2004, European Patent Office, Netherlands.
Anger, T. et al., “Medicinal Chemistry of Neuronal Voltage-Gated Sodium Channel Blockers”,Journal of Medicinal Chemistry, vol. 44, No. 2, pp. 115-137, published on web Jan. 11, 2001.
Kyle Donald J.
Sun Qun
Zhou Xiaoming
Euro-Celtique S.A.
Freistein Andrew B.
McKane Joseph K.
LandOfFree
Aryl substituted benzimidazoles and their use as sodium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl substituted benzimidazoles and their use as sodium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted benzimidazoles and their use as sodium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542441